Literature DB >> 33507114

Percutaneous coronary intervention in patients with cardiac allograft vasculopathy: a Nationwide Inpatient Sample (NIS) database analysis.

Waqas Ullah1, Nishant Thalambedu1, Salman Zahid2, Muhammad Zia Khan3, Tanveer Mir4, Sohaib Roomi1, David L Fischman5, Salim S Virani6,7, Mahboob Alam6.   

Abstract

Cardiac allograft vasculopathy (CAV) is a major cause of heart transplant failure and mortality. The role of percutaneous coronary intervention (PCI) in these patients remains unknown.
Methods: The National Inpatient Sample (NIS) (2015-2017) was queried to identify all cases of CAV. The merits of PCI were determined using a propensity-matched multivariate logistic regression model. Adjusted odds ratios (aOR) for in-hospital complications were calculated.
Results: A total of 2,380 patients (PCI 185, no-PCI 21,95) with CAV were included in the analysis. There was no significant difference in the odds of major bleeding (OR 1.87, 95% CI 0.94-3.7, P = 0.11), post-procedure bleeding (P = 0.37), cardiogenic shock (OR 0.87, 95% CI 0.45-1.69, P = 0.80), acute kidney injury (uOR 0.92, 95% CI 0.68-1.24, P = 0.64), cardiopulmonary arrest (OR 0.84, 95% CI 0.34-2.11, P = 0.88), and in-hospital mortality (OR 1.59, 95% CI 0.91-2.79, P = 0.14) between patients undergoing PCI compared to those treated conservatively. A propensity-matched analysis closely followed the results of unadjusted crude analysis.
Conclusion: PCI in CAV may be associated with increased in-hospital complications and higher resource utilization.

Entities:  

Keywords:  CAV; PCI; Transplant; cardiac allograft vasculopathy; percutaneous coronary intervention

Year:  2021        PMID: 33507114     DOI: 10.1080/14779072.2021.1882851

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  1 in total

1.  Coronary allograft vasculopathy managed by Flash ostial balloon in a pediatric patient.

Authors:  Viral K Desai; Mohammad Mathbout; Apurv Agarwal; Ibrahim Fahsah; Shahab Ghafaghazi
Journal:  Glob Cardiol Sci Pract       Date:  2021-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.